The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial - Sandhu, Shahneen K; Schelman, William R; Wilding, George; Moreno, Victor; Baird, Richard D; Miranda, Susana; Hylands, Lucy; Riisnaes, Ruth; Forster, Martin; Omlin, Aurelius; Kreischer, Nathan; Thway, Khin; et al. (The lancet oncology, 2013)
Keywords: Adult; Aged; BRCA1 Protein - genetics; BRCA2 Protein - genetics; Cohort Studies; DNA repair; Drug dosages; Ewings sarcoma; Female; Follow-Up Studies; Genes; Hematology; Hematology, Oncology, and Palliative Medicine; Heterozygote; Humans; Indazoles - pharmacokinetics; Indazoles - therapeutic use; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Mutation - genetics; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - genetics; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Neutropenia; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Patients; Piperidines - pharmacokinetics; Piperidines - therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostate cancer; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Tissue Distribution; Toxicity; Tumors; United States--US